Investigating how a specific protein affects immune response in triple-negative breast cancer
Immunosuppressive impact of the GPCR/MALT1 protease axis in triple-negative breast cancer
This study is looking at how a protein called MALT1 affects triple-negative breast cancer and how it might be making it harder for the immune system to fight the cancer, with the hope of finding better treatments that help boost the immune response.
Quick facts
| Grant type | Fellowship grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Pittsburgh at Pittsburgh NIH-funded |
| Lab location | 1 site (Pittsburgh, United States) |
| Project ID | NIH-10994892 on NIH RePORTER |
What this research studies
This research focuses on understanding the role of the MALT1 protein in triple-negative breast cancer (TNBC), a type of breast cancer that currently lacks effective targeted therapies. The study aims to explore how MALT1 contributes to immunosuppression within the tumor microenvironment, potentially hindering the effectiveness of immunotherapy. By utilizing advanced techniques such as CRISPR, researchers will investigate the mechanisms by which MALT1 influences tumor progression and immune cell behavior. This could lead to new strategies for enhancing immune responses against TNBC.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with triple-negative breast cancer who may benefit from novel immunotherapeutic approaches.
Not a fit: Patients with other subtypes of breast cancer or those who do not have a diagnosis of breast cancer may not receive benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved immunotherapy options for patients with triple-negative breast cancer.
How similar studies have performed: Other research has shown promising results in targeting similar pathways in cancer treatment, indicating potential for success in this approach.
Where this research is happening
Pittsburgh, United States
- University of Pittsburgh at Pittsburgh — Pittsburgh, United States (Active)
Researchers
- Principal investigator: Little, John Walton — University of Pittsburgh at Pittsburgh
- Study coordinator: Little, John Walton
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.